Our success stories

Read the stories from the teams behind some of our most important achievements, from bringing drugs to market to spinning out new companies and developing essential partnerships.

Bispecific antibody coloured heavy chain in green and pink, light chain blue and yellow against grey background; glycosylated bispecific immunoglobulin engineered to target different antigens 3D render

MOv18 – opening a new front for immunotherapy

Tumour cells under microscope labelled with fluorescent molecules

A new culture – how CRUK is helping to take organoids global

The power of partnership – the unique alliance taking on brain cancer

A new approach to cancer immunotherapy

The story of gamma delta T cells from discovery to clinical trials

Taking on DNA repair to tackle cancer

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials – we tell the...

Speaking a thousand words – how a cancer image collection is set to improve AI diagnosis

Artificial intelligence is set to revolutionise many aspects of cancer diagnosis and treatment – but an AI is only as good as the data used to train...

Photomicrograph of a diffuse large B-cell lymphoma

Coming together for Zynlonta

How scientific expertise, funding and entrepreneurship came together for the development of an antibody-drug conjugate targeting lymphoma

How UK researchers commercialised CD25 as an immunotherapy drug target

Guided by Cancer Research Horizons in collaboration with Roche, Cancer Research UK scientists develop a new antibody that can target CD25 and harness...

PARP inhibitors: Halting cancer by halting DNA repair

PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate, and other types of cancer. To develop these drugs, researchers...